Zydus Lifesciences buyback 2026: ₹1,100 cr at ₹1,150

What the board approved on May 19

Zydus Lifesciences said its board, at a meeting held on May 19, 2026, approved a proposal to buy back fully paid-up equity shares through the tender offer route. The buyback size is capped at an aggregate amount not exceeding ₹1,100 crore, payable in cash. The company set the buyback price at ₹1,150 per equity share. The announcement came alongside the company’s January to March quarter results for FY2025-26 (Q4FY26). Reports around the results also said profit, revenue, and margins beat Street estimates, though the company’s specific quarterly financial numbers were not detailed in the provided information.

The company also stated that promoters will participate in the buyback. Separately, management commentary highlighted that the India business performed well in the quarter, rising about 14% year-on-year, with the Consumer Wellness and Intramuscular Formulations segment leading.

Buyback size, share count, and tender route

As per the board approval, Zydus Lifesciences will buy back up to 95,65,217 equity shares, commonly cited as 95.65 lakh shares. These shares represent 0.95% of the company’s equity stake, based on the details shared in market reports. The buyback is structured as a tender offer, which typically allows eligible shareholders to tender shares during the offer period at the announced price.

The buyback consideration is capped at ₹1,100 crore. The buyback price of ₹1,150 per share was described as being at a premium of 16% compared with the company’s closing price on the preceding Monday.

Record date set for shareholder eligibility

Zydus Lifesciences fixed May 29, 2026 as the record date. This date will be used to determine which shareholders are eligible to participate in the buyback. Multiple reports repeated May 29, 2026 as the record date for the buyback.

The company also clarified that promoters will participate, and the same record date will be used to determine eligibility for shareholders.

How the stock moved after the announcement

Zydus Lifesciences shares gained over 5% on Tuesday, May 19, after the buyback approval and the March quarter performance update. On the NSE, the stock touched an intraday high of ₹1,048 per share. Another update said the stock was trading 5.3% higher at ₹1,047 after the earnings announcement.

A separate market update in Hindi noted that the stock hit ₹1,048 intraday and later closed at ₹1,018, up 2.80% for the day after some profit-taking near the close. Another report cited an intraday high of ₹984.9 on the BSE, with the stock up 4.77% at ₹983.75 at 10:47 AM.

The stock is also reported to be up 14% so far in 2026.

Promoter holding and participation

As per the March quarter shareholding pattern referenced in market coverage, promoters held a 75% stake in Zydus Lifesciences. The same reports said promoters will participate in the buyback.

Promoter participation matters for tender-offer buybacks because it can influence the final acceptance ratio across shareholder categories. However, the specific acceptance ratios and category-wise entitlements were not provided in the available information.

Dividend recommendation alongside buyback

Along with the buyback, the board also recommended a final dividend of ₹1 per equity share for FY26. The dividend proposal will be placed for shareholder approval at the company’s annual general meeting scheduled for August 11, 2026.

No additional dividend record date or payment timeline was provided in the supplied details beyond the AGM date.

Compliance framework and trading window closure

In exchange communications, Zydus Lifesciences said the buyback proposal was considered under the Companies Act, 2013 and SEBI (Buy-back of Securities) Regulations, 2018, as amended, along with other applicable laws. The company also referenced SEBI (Prohibition of Insider Trading) Regulations, 2015 for trading window norms.

It said the trading window for Directors and Designated Persons would remain closed until May 21, 2026, and reopen from May 22, 2026. The trading window was also deemed closed in connection with the buyback proposal, as per applicable regulations.

Snapshot of key buyback facts

Earlier buybacks: 2024 and 2022 references

The current proposal follows earlier buybacks referenced in market coverage. Zydus Lifesciences previously carried out a ₹600 crore buyback at ₹1,005 per share via the tender route. That offer involved up to 59,70,149 equity shares of face value ₹1 each, opened on February 29 and closed on March 6, with the record date and ex-date cited as February 23.

Before that, the company executed a ₹750 crore buyback in 2022, as referenced in the same set of reports.

What investors will track next

The immediate date highlighted by the company is May 29, 2026, the record date that determines eligibility for the buyback. Investors will also watch for subsequent company filings that lay out the offer timeline and tendering process details.

Separately, shareholders will track the annual general meeting on August 11, 2026, where the final dividend of ₹1 per equity share for FY26 is set to be placed for approval. The company has also disclosed the trading window schedule for Directors and Designated Persons, with reopening from May 22, 2026.